Press Room


Pet Cancer Therapeutics Market to exceed $300mn by 2024

Pet Cancer Therapeutics Market size to exceed USD 300 million by 2024, as per a new research report by Global Market Insights, Inc.
 

Growing pet adoption rate coupled with increasing disposable income of pet owners will drive pet cancer therapeutics market growth. Strong and robust drug pipeline for treatment of pet cancer will stimulate business growth over the forecast years.
 

High cost of pet cancer drugs along with rising instances of adverse drug events should hamper industry growth over the forecast years. Lack of awareness regarding pet diseases among the pet owners will impede industry expansion.

 

 Request Sample Buy NowInquiry Before Buying

 

Browse key industry insights spread across 95 pages with 80 market data tables & 9 figures & charts from the report, Pet Cancer Therapeutics Market Size By Medicine Type (Chemotherapy Drugs and Vaccines), By Species (Dogs and Cats), By Cancer Type (Lymphoma, Mast Cell Cancer Tumors, Melanoma, Mammary and Squamous Cell Cancer), Regional Outlook (U.S., Canada, Germany, UK, Spain, Italy, France, China, Japan, India, Australia, Brazil, Mexico), Technology Development, Competitive Landscape & Forecast, 2017 – 2024 in detail along with the table of contents:
https://www.gminsights.com/industry-analysis/pet-cancer-therapeutics-market
 

Chemotherapy has been the mainstream medication for pet cancers till recent times. However, immunological vaccines entered the market and are gaining significant market share. With number of chemotherapy drugs in pipeline, the industry should witness considerable growth over the coming years.
 

Dogs are more prone to develop cancer than cats and the healthy pipeline will drive segment growth over the forecast years. However, introduction of specialized cat cancer medicines will stimulate the cat cancer therapeutics market growth.
 

Pet healthcare companies are focusing on development of drugs for mast cell cancer and melanoma among other cancer types. This trend will witness change as medicines to treat lymphoma and mammary cell cancer are in the pipeline. Innovative medicines for treatment of multiple cancer tumors is anticipated to accelerate business growth.
 

U.S. pet cancer therapeutics market holds the largest revenue share in 2016. Presence of large number of pet drug manufacturing companies, quick adoption of innovative pet care medicines and increasing disposable income of pet owners will boost industry growth.
 

Australia pet cancer therapeutics market held highest regional revenue share in 2016 owing to growing pet-keeping trend, availability of innovative pet care medicines and increasing disposable income of pet owners.
 

Some of the leading industry players include Zoetis, Merial, Aratana Therapeutics, AB Science, Vetivax, Oasmia Pharmaceutical, VetDC, Regeneus, CanFel Therapeutics, Karyopharms Verdinexor. The most commonly adopted business strategies by industry participants includes new product launches, regional expansion and mergers and acquisition.
 

Pet cancer therapeutics market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2013 to 2024, for the following segments:

Pet Cancer Therapeutics Market By Medicine Type

  • Chemotherapy drugs
  • Vaccines

Pet Cancer Therapeutics Market By Species

  • Dogs
  • Cats

Pet Cancer Therapeutics Market By Cancer Type

  • Lymphoma
  • Mast cell cancer
  • Melanoma
  • Mammary and Squamous cell cancer

The above information is provided for the following regions/countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Italy
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
  • Latin America
    • Brazil
    • Mexico